Cedience Launches Cedience Labs to Empower Regulatory Teams with AI-Powered Workflows

Cedience, the regulatory-first AI company supporting drug development teams with innovative research and intelligence technology, today announced the launch of Cedience Labs, a new platform enabling teams to experiment with cutting-edge, AI-powered tools that support decision-making at critical points in drug development.

Cedience Labs provides a secure environment where regulatory teams can explore advanced AI capabilities-particularly large language model (LLM) technologies-without disrupting existing processes or enterprise systems. The platform reflects Cedience's commitment to enabling regulatory organizations to modernize their toolkits with a value-first approach, grounded in real-world regulatory use cases.

"The biopharmaceutical industry is rapidly adopting AI and LLM-based technologies, with many enterprise-wide initiatives well underway," said Amin Osmani, CEO of Cedience. "Cedience Labs was created to give regulatory professionals a practical way to engage with these innovations without delay-allowing them to enhance their workflows, not replace them."

Re-inventing the Regulatory Toolbox
Regulatory teams face increasing complexity as global health authorities and their guidelines or requirements evolve with the industry. Cedience Labs addresses this challenge by enabling hands-on experimentation with AI-driven tools that align with how regulatory work is actually performed.

Through Cedience Labs, regulatory professionals can explore AI-supported workflows such as:
- Monitoring and interpreting changes in the global regulatory environment
- Assessing the potential impact of regulatory updates
- Establishing regulatory precedents across indications, regions, and products
- Preparing for agency meetings and interactions
- Analyzing and benchmarking regulatory review timelines

All workflows are designed to integrate seamlessly into existing regulatory processes, allowing teams to enhance efficiency and insight without operational disruption.

Built for Today's AI-Enabled Enterprise
As AI adoption accelerates across biopharma, Cedience Labs offers a pragmatic bridge between experimentation and enterprise readiness. The platform enables regulatory teams to evaluate emerging AI capabilities, understand their value, and build confidence before broader organizational deployment.

"Our team has built the AI building blocks regulatory teams need to capture the value from LLMs without complex development cycles," said Andy Nanopoulos, CTO of Cedience. "Cedience Labs provides modular, workflow-ready components that can be applied directly to real regulatory questions, allowing teams to move from experimentation to impact quickly and responsibly."

By abstracting the complexity of large language models and embedding them into familiar regulatory workflows, Cedience Labs helps organizations realize value from AI while maintaining governance, traceability, and alignment with existing operating models. Regulatory teams can incrementally enhance their capabilities, test new approaches, and scale successful use cases at their own pace.

Cedience Inc.
110 James St.
St. Catharines, ON
Canada L2R 7E8

About Cedience
Cedience is a regulatory-first company unlocking the potential of artificial intelligence to support critical decision-making in drug development. By combining deep regulatory expertise with advanced artificial intelligence, Cedience helps biopharmaceutical teams navigate complexity, anticipate change, and make informed decisions with confidence.

For more information about Cedience and its regulatory intelligence solutions, visit www.cedience.com.

This release was published on openPR.